Antares Pharma Inc

Type: Company
Name: Antares Pharma Inc
Nationality: United States
Web Address: http://www.antarespharma.com/
First reported 21 hours ago - Updated 21 hours ago - 1 reports

Antares Pharma Q1 net loss increases

Antares Pharma, Inc., a provider of self-administered parenteral pharmaceutical products and topical gel-based medicines, has reported that net loss for the first quarter ended March 31, 2013 was $3.41 million, or $0.03 loss per share, compared to a net ... [Published Individual.com - 21 hours ago]
First reported May 20 2013 - Updated May 20 2013 - 1 reports
Accuray Inc
Accuray Inc

StockCall Pre-Market Review on AMRN, ARAY, ATRS, and ANTH

StockCall.com Provides Stock Research on Amarin Corp. plc, Accuray Inc., Antares Pharma Inc., and Anthera Pharmaceuticals Inc. New York City, New York -- (May 20, 2013)The healthcare sector has been facing significant challenges over the last few years. ... [Published Individual.com - May 20 2013]
First reported May 17 2013 - Updated May 18 2013 - 2 reports
FDA Food & Drug Administration
FDA Food & Drug Administration

3 Most Important Upcoming FDA Decisions of 2013

Filed under: InvestingRegulatory decisions made by the Food and Drug Administration (FDA) often serve as important catalysts for pharmaceutical stocks. In the following video, health-care analyst Max Macaluso discusses three upcoming FDA decisions -- ... [Published Daily Finance - May 17 2013]
First reported May 17 2013 - Updated May 17 2013 - 1 reports

Antares Pharma to Present at the Bank of America Merrill Lynch 2013 Healthcare Conference

(NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Antares Pharma, Inc. (NASDAQ: ATRS) announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2013 Healthcare ... [Published NewsRX - May 17 2013]
First reported May 09 2013 - Updated May 09 2013 - 4 reports

Antares Pharma to Present at the Bank of America Merrill Lynch 2013 Healthcare Conference

Filed under: Investing EWING, N.J.--( BUSINESS WIRE )-- Antares Pharma, Inc. ( NAS: ATRS ) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2013 Healthcare Conference ... [Published Daily Finance - May 09 2013]
First reported May 08 2013 - Updated May 08 2013 - 1 reports
Antares Pharma Inc
Antares Pharma Inc

Form 4 ANTARES PHARMA, INC. For: May 06 Filed by: Wotton Paul K

StreetInsider.com - Form 4 ANTARES PHARMA, INC. For: May 06 Filed by: Wotton Paul K ... [Published Street Insider - May 08 2013]
Entities: Antares Pharma Inc
First reported May 08 2013 - Updated May 08 2013 - 1 reports

Form 4 ANTARES PHARMA, INC. For: May 06 Filed by: DAVE KAUSHIK J

StreetInsider.com - Form 4 ANTARES PHARMA, INC. For: May 06 Filed by: DAVE KAUSHIK J ... [Published Street Insider - May 08 2013]
Entities: Antares Pharma Inc
First reported May 08 2013 - Updated May 08 2013 - 1 reports

Form 4 ANTARES PHARMA, INC. For: May 06 Filed by: APPLE ROBERT F

StreetInsider.com - Form 4 ANTARES PHARMA, INC. For: May 06 Filed by: APPLE ROBERT F ... [Published Street Insider - May 08 2013]
Entities: Antares Pharma Inc
First reported May 08 2013 - Updated May 08 2013 - 2 reports

Antares Pharma Management Discusses Q1 2013 Results - Earnings Call Transcript

8:30 AM ETOperatorGood morning, ladies and gentlemen, and welcome to the Antares First Quarter 2013 Operating and Financial Results Conference Call. [Operator Instructions] I would now like to turn the call over to Jack Howarth, Antares Vice President ... [Published Seeking Alpha - May 08 2013]
First reported May 08 2013 - Updated May 08 2013 - 4 reports

Antares Pharma, Inc. (AIS) Reports First Quarter 2013 Operating and Financial Results

Staying up-to-date has never been simpler. Sign up for the today! (NASDAQ: ATRS) today reported operating and financial results for the first quarter ended March 31, 2013. Quarter and Recent Highlights â¢Announced acceptance of the OTREXUP⢠New Drug ... [Published BioSpace - May 08 2013]
First reported May 08 2013 - Updated May 08 2013 - 1 reports

Antares Pharma (ATRS) Announces Quarterly Results

Antares Pharma (NASDAQ: ATRS) issued its quarterly earnings data on Wednesday. The company reported ($0.03) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.03), StockRatingsNetwork reports. The company had revenue of $4.50 million ... [Published American Banking News - May 08 2013]
First reported May 01 2013 - Updated May 01 2013 - 1 reports

ANTARES PHARMA INC: Antares Pharma to Host First Quarter 2013 Operating and Financial Results Conference Call

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its first quarter 2013 operating and financial results before the market opens on Wednesday, May 8, 2013, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) ... [Published 4 Traders - May 01 2013]

Quotes

...We are working closely with the FDA on the OTREXUP NDA file and look forward to meeting the PDUFA target date." Dr Wotton continued, "While we work through the review process with the FDA, the commercial team has validated the market potential for OTREXUP. Independent research indicates there is a clear value proposition in the optimization of methotrexate through subcutaneous self-administration for both patients and third-party payers. Therefore, we believe that OTREXUP could expand physician treatment options for patients with rheumatoid arthritis and or psoriasis."
Antares Pharma Q1 net loss increases [Published Individual.com - 21 hours ago]
...The age-old saying goes: "If it keeps you up at night, then it is best avoided" ; sadly, this mantra has steered many astute individuals clear of emerging growth investments for multiple generations...
Long-Term Biotech: 3 Names To Discover Now [Published Seeking Alpha - May 21 2013]
Research and Markets (http://www.researchandmarkets.com/research/sl9ffd/injectable_drug) has announced the addition of the "Injectable Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Global Forecasts to 2017" report to their offering. The global injectable drug delivery technologies market was valued at $22.5 billion in 2012, and is expected to reach $43...
Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 [Published Individual.com - May 08 2013]
..." Dr. Wotton continued, "This patent focuses on the interface between injection devices and the patient. It demonstrates that Antares understands that self-injection requires unique device features for the home setting where a growing number of injectables are being used."
Antares Pharma Gets New Patent on VIBEX Device Platform [Published Individual.com - Apr 19 2013]

More Content

All (97) | News (54) | Reports (9) | Blogs (9) | Audio/Video (0) | Fact Sheets (0) | Press Releases (25)
sort by: Date | Relevance
Antares Pharma Q1 net loss increases [Published Individual.com - 21 hours ago]
Long-Term Biotech: 3 Names To Discover Now [Published Seeking Alpha - May 21 2013]
StockCall Pre-Market Review on AMRN, ARAY, ATRS... [Published Individual.com - May 20 2013]
Antares Pharma, Inc. (ATRS) - Medical Equipment... [Published TransWorldNews - May 19 2013]
3 Most Important Upcoming FDA Decisions of 2013 [Published Daily Finance - May 17 2013]
3 Most Important Upcoming FDA Decisions of 2013 [Published Motley Fool Discussion Boards - May 17 2013]
Antares Pharma to Present at the Bank of Americ... [Published NewsRX - May 17 2013]
Antares Pharma, Inc. (ATRS) - Product Pipeline ... [Published companiesandmarkets.com - May 15 2013]
Contraceptive Ring: Another Under-The-Radar Cat... [Published BioPortfolio - May 15 2013]
Antares Pharma Releases 1Q 2013 Operating and F... [Published Individual.com - May 13 2013]
Earnings Volatility Drives These Healthcare Sto... [Published Wall St. Cheat Sheet - May 12 2013]
Earnings Volatility Drives These Healthcare Sto... [Published Wall St. Cheat Sheet - May 12 2013]
Antares Pharma to Present at the Bank of Americ... [Published Daily Finance - May 09 2013]
ANTARES PHARMA INC: Antares Pharma to Present a... [Published 4 Traders - May 09 2013]
Antares Pharma to Present at the Bank of Americ... [Published Yahoo! Finance - May 09 2013]
Antares Pharma to Present at the Bank of Americ... [Published Reuters - May 09 2013]
Antares Pharma to Present at the Bank of Americ... [Published Business Wire Health News - May 09 2013]
Merck Announces FDA Acceptance of BLA for Inves... [Published BioMedReports - May 09 2013]
Form 4 ANTARES PHARMA, INC. For: May 06 Filed b... [Published Street Insider - May 08 2013]
Form 4 ANTARES PHARMA, INC. For: May 06 Filed b... [Published Street Insider - May 08 2013]
Form 4 ANTARES PHARMA, INC. For: May 06 Filed b... [Published Street Insider - May 08 2013]
U.S./Canada daily earnings hits & misses May 8 ... [Published Globe and Mail - May 08 2013]
Antares Pharma Management Discusses Q1 2013 Res... [Published Seeking Alpha - May 08 2013]
Antares Pharma, Inc. (AIS) Reports First Quarte... [Published BioSpace - May 08 2013]
Antares Pharma Inc (ATRS) Q1 Results Unimpressi... [Published InsiderMonkey.com - May 08 2013]
Antares Q1 Results Unimpressive, but Otrexup Co... [Published Motley Fool Discussion Boards - May 08 2013]
Antares Pharma, Inc. Reports First Quarter 2013... [Published BioSpace - May 08 2013]
Injectable Drug Delivery Market by Formulations... [Published Individual.com - May 08 2013]
ANTARES PHARMA INC: 8 May 2013 Antares Pharma R... [Published 4 Traders - May 08 2013]
Antares Pharma (ATRS) Announces Quarterly Results [Published American Banking News - May 08 2013]
1 2 3 4
In Focus
  •  
Paul Wotton, Max Macaluso, Barack Obama, [more]
  •  
Teva Pharmaceutical Industries Ltd, Ferring AB, Bank of America Merrill Lynch, [more]
  •  
FDA Food & Drug Administration, United States Patent And Trademark Office, US Securities and Exchange Commission, [more]
  •  
Healthcare Conference, Patent, New Drug Application, [more]
  •  
LibiGel, Cinryze, Xignite Financials, [more]
  •  
London, Sarepta (United States), Trenton (New Jersey, United States), [more]
  •  
United States, Canada, North Korea, [more]
  •  
Diseases, Medication, Research & Development, [more]
  •  
Banking & Financial Services, Health, Paper & Packaging, [more]
Business Wire Health News, 4 Traders, Yahoo! Finance, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Earnings Volatility Drives These Healthcare Sto... [Published Wall St. Cheat Sheet - May 12 2013]
Antares Pharma Inc ( NASDAQ:ATRS ) had a loss and met Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share decreased to $-0.03 in the quarter versus EPS of $0.00 in the year-earlier quarter. Revenue ...
Earnings Volatility Drives These Healthcare Sto... [Published Wall St. Cheat Sheet - May 12 2013]
Antares Pharma Inc ( NASDAQ:ATRS ) had a loss and met Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share decreased to $-0.03 in the quarter versus EPS of $0.00 in the year-earlier quarter. ...
4 Healthcare Stock Stories for Weekend Perusal [Published Wall St. Cheat Sheet - Apr 05 2013]
Arena Pharmaceuticals  ( NASDAQ:ARNA ): Current price $8.12 Arena reported Friday the start of dosing in a Phase 1 clinical trial of APD334, which is a novel oral drug candidate that aims at the sphingosine 1-phosphate subtype 1 receptor for the potential ...
General Motors Ponders The North Korea Situatio... [Published Wall St. Cheat Sheet - Apr 05 2013]
General Motors  ( NYSE:GM ) has a busy week coming up. CEO Dan Akerson is planning to visit Germany, to visit with chancellor Angela Merkel and discuss plans to restructure the company’s labor agreements. GM is exploring the option of closing its Opel ...
4 Healthcare Stock Stories for Wednesday Invest... [Published Wall St. Cheat Sheet - Apr 03 2013]
Novavax ( NASDAQ:NVAX ): Current price $2.35 The company has announced that top-line data from the Phase II dose-ranging clinical trial of its respiratory syncytial virus vaccine candidate in women of childbearing age, attained the trial’s protocol-specified ...
1 2

Press Releases

sort by: Date | Relevance
Antares Pharma to Present at the Bank of Americ... [Published Business Wire Health News - May 09 2013]
Antares Pharma Reports First Quarter 2013 Opera... [Published Business Wire Health News - May 08 2013]
Antares Pharma to Host First Quarter 2013 Opera... [Published Business Wire - May 01 2013]
Antares Pharma to Host First Quarter 2013 Opera... [Published Business Wire Health News - May 01 2013]
Antares Pharma Announces the Issuance of a New ... [Published Business Wire Health News - Apr 16 2013]
1 2 3 4 5
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.